ALKERMES | ALKS - 销售收入

股票价格

33.31

每天变化

-0.60 -1.77%

每月一次

13.42%

每年

19.65%

Q2 预测

32.32

金融业

USD

USD 2.49B

现金及等价物

USD 388.57M

USD 46.21M

USD 1.93B

USD 543.44M

USD 71.6M

股息收益率

0

USD -10.95M

USD 100.31M

1.8K

EPS每股收益

USD 0.29

股本和储备

USD 1.82B

USD 338.34M

债务利息支出

USD 12.28M

USD 11.94M

USD 285.82M

USD 5.49B

USD 49.34M

USD 326.44M

USD -10.95M

普通股股本

USD 165.61M

19.54

USD 100.74M

USD 384.5M

销售和管理费用

USD 187.2M

USD 196.63M

贸易债权人

USD 107.95M

应收帐款人

USD 334.03M

	销售	更改		日
AbbVie	USD 16.62B		840M	2025-12
Acadia Pharmaceuticals	USD 284M		5.4M	2025-12
ALKERMES	USD 384.5M		9.7M	2025-12
Amgen	USD 9.9B		340M	2025-12
Biogen	USD 2.28B		250M	2025-12
BioMarin Pharmaceutical	USD 875M		99M	2025-12
Bristol-Myers Squibb	USD 12.5B		300M	2025-12
Coherus Biosciences	USD 12.75M		1.18M	2025-12
Eli Lilly	USD 19.3B		1.7B	2025-12
Gilead Sciences	USD 7.93B		130M	2025-12
Heron Therapeutics	USD 40.59M		2.38M	2025-12
Ionis Pharmaceuticals	USD 203M		46M	2025-12
J&J	USD 24.1B		500M	2026-03
Merck	USD 16.4B		880M	2025-12
Minerva Neurosciences	USD 0		0	2024-09
Nektar Therapeutics	USD 21.81M		2.32M	2025-12
Neurocrine Biosciences	USD 805.5M		10.6M	2025-12
Otsuka Holdings	JPY 650.15B		12.17B	2025-12
Pfizer	USD 17.58B		880M	2025-12
Regeneron Pharmaceuticals	USD 3.88B		130M	2025-12
Vertex Pharmaceuticals	USD 3.19B		110M	2025-12